STRIVE/VU.2 | NCT06358469

Primary Objective - To estimate the 3-year local recurrence rates in patients with HPV-A and HPV-I VSCC surgically managed based on dVIN/p53 status and tumour margin clearance.

STRIVE/VU.2 | NCT063584692026-03-12T21:02:36+11:00

DOVE | APGOT-OV7/ENGOT-ov80

The DOVE trial is a Phase II, randomised study evaluating the efficacy and safety of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynaecological clear cell carcinoma.

DOVE | APGOT-OV7/ENGOT-ov802026-03-12T21:02:42+11:00
Go to Top